Efficacy of Botulinum Toxin A in the Treatment of Bruxism-related Symptomatology
NCT ID: NCT04722809
Last Updated: 2024-08-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE3
1 participants
INTERVENTIONAL
2022-05-25
2022-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Most often, it is primary or idiopathic bruxism, however when it is related to a cause it is qualified as secondary.
Primary bruxism is a condition that is not well known to the general public, but I is very widespread (12% of the adult population). In addition, it can alter quality of life, as a result of associated sleep disorders, concentration disorders, daytime fatigue, chronic pain, etc.
The current treatment for this condition is only symptomatic. Currently, one of the most effective treatments is the intramuscular injection of botulinum toxin A in the muscles of mastication. The progressive anticholinergic action results in a reduction of functional signs (dental pain, periodontal pain, temporomandibular joint pain, tension headaches, neck pain) and physical signs (reduction of the mass of the injected muscles, alba linea, tongue scalloping, limitation or stability of dental damage).
However, these clinical data are practically not objectified in daily practice. Objective criteria would make it possible to measure the effectiveness of the treatment, to follow the patient, and to identify the early symptoms in order to prevent a recurrence.
The aim of the prospective study is to concretely measure the strength and electromyographic activity of the muscles of mastication before and after botulinum toxin injection.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Use of Low-Dose Botulinum Toxin Injection Into the Masseter Muscle to Treat Sleep Bruxism
NCT05620316
Clinical Performance of Therapeutic Use of BTX for Bruxism
NCT06258070
Botulinum Toxin A Injectable Solution in the Management of Bruxism: A Clinical Trial Study
NCT03827122
Study of the Safety and Efficacy of Botox in Bruxism
NCT00908050
Bruxism Xeomin® Intervention Trial
NCT04792398
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Symptomatic patients in the context of bruxism
Botulinum toxin injection
Injection in the temporal and masseter muscles: in 3 points in the masseter muscles and in 2 points in the temporal muscles.
QOL-Brux
Questionnaire evaluating the symptoms of bruxism Inclusion and 3 months post-injection
Muscular strength of the jaw
Measurement in the jaw with a dynamometer connected to a sensor placed on the 1st molar on the right side.
At inclusion and 1 month post-injection.
Intensity and frequency of episodes of nocturnal bruxism
Measurements via a portable electromyography system, coupled with a heartbeat sensor (Bruxoff®). Measurements performed during normal sleeping conditions at home before injection and 1 month after.
visual analogue pain scale
Evaluation of jaw pain. At inclusion and 3 months post-injection
Endobuccal and linea alba photographs
anonymous endobuccal and linea alba photographs (line on the inner face of the cheeks as the result of chronic friction).
At inclusion
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Botulinum toxin injection
Injection in the temporal and masseter muscles: in 3 points in the masseter muscles and in 2 points in the temporal muscles.
QOL-Brux
Questionnaire evaluating the symptoms of bruxism Inclusion and 3 months post-injection
Muscular strength of the jaw
Measurement in the jaw with a dynamometer connected to a sensor placed on the 1st molar on the right side.
At inclusion and 1 month post-injection.
Intensity and frequency of episodes of nocturnal bruxism
Measurements via a portable electromyography system, coupled with a heartbeat sensor (Bruxoff®). Measurements performed during normal sleeping conditions at home before injection and 1 month after.
visual analogue pain scale
Evaluation of jaw pain. At inclusion and 3 months post-injection
Endobuccal and linea alba photographs
anonymous endobuccal and linea alba photographs (line on the inner face of the cheeks as the result of chronic friction).
At inclusion
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient between 18 and 64 years of age.
* Patient who has never received botulinum toxins
* Symptomatic patient in the context of bruxism in failure to the usual treatments (analgesic, physiotherapy, relaxation technique and maxillary retainer)
* Woman of childbearing age using an effective method of contraception
* Symptomatic patients in the context of bruxism, without a maxillary disocclusion retainer.
Exclusion Criteria
* Patient not affiliated to the national health insurance system
* Pregnant or breastfeeding woman
* Refusal to take part in the study
* Neuromuscular diseases, including Myasthenia gravis, Myopathies, Amyotrophic Lateral Sclerosis. Lambert-Eaton Syndrome, patients with peripheral motor neuropathies, patients with underlying neurological disorders.
* Patients with a history of cardiovascular disease
* Patients with epilepsy or a previous seizure episode
* Neurogenic impairment of the face (including facial paralysis, polyradiculoneuritis)
* History of dysphagia or pulmonary aspiration
* Injection site infection (masseter and temporal)
* Hypersensitivity or allergy to botulinum toxin or any of its excipients.
* Treatment with aminoglycosides or anticholinesterase agents.
18 Years
64 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Universitaire Dijon
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chu Dijon Bourgogne
Dijon, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ZWETYENGA CRBFC 2020
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.